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ABSTRACT 48 
Data about patient-reported outcomes from cancer genetics services (CGS) are 49 
lacking but are essential to guide service evaluation and improvements. We measured 50 
improvement in empowerment, following genetic counseling in Singapore using a 51 
culturally-adapted version of the Genetic Counseling Outcome Scale (GCOS-24); and 52 
sought to identify factors associated with change in empowerment. The GCOS-24 was 53 
administered to 155 patients of the CGS, at pre- and post-counseling or testing 54 
timepoints. Of which, 110 patients underwent genetic testing. Individual pre- and post-55 
counseling responses were subjected to Rasch analysis; the scale was subsequently 56 
split into Cognitive Control (CC) and Emotional Control (EC) domains. Associations of 57 
baseline characteristics with changes in pre- and post-CC and EC scores were 58 
assessed using multiple regression analysis. Both CC and EC scores showed 59 
significant improvement following genetic counseling and testing. While all items in the 60 
CC domain of being showed increases at follow-up, aspects of EC related to alleviating 61 
negative emotions (p = 0.88) and hopelessness (p = 0.2) did not demonstrate 62 
significant improvement. Our study revealed significant improvement in patient 63 
empowerment in patients who have received cancer genetic counselling, while 64 
revealing a need to cultivate hope and facilitate the alleviation of negative emotions in 65 
patients during genetic counselling. 66 
 67 
Word count: 200 68 
 69 
Keywords: Genetic Counseling, Genetic Testing, Genetic Services, Rasch Analysis, 70 
Regression Analysis, Hope 71 
 72 
 73 
 74 
75 
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INTRODUCTION 76 
 77 
Genetic counseling is a communication process which aims to help individuals and 78 
families understand and adapt to the medical, psychological, familial and reproductive 79 
implications of a heritable genetic condition.1,2 Though the practice of clinical genetics 80 
was established in the 1970s,3 evaluation of its impact on patient-reported outcomes 81 
has been lacking, due to the paucity in the availability of robust outcomes.4,5  82 
In Singapore, there is a growing demand for cancer genetic services6,7 and, as such, 83 
it is a priority to evaluate patient-reported outcomes from genetic counseling and 84 
testing. The lack of such information impedes progress in the field, as evidence-based 85 
improvements cannot be made. 86 
The  Genetic Counseling Outcome Scale (GCOS-24) (Supplementary Materials 1) 87 
is a validated genetics-specific Patient Reported Outcome Measure (PROM) and 88 
assesses patient-reported outcomes from genetic counseling and testing.8 It captures 89 
a construct coined ‘empowerment’, defined as ‘a set of beliefs that enable a person 90 
from a family affected by a genetic condition to feel that they have some control over 91 
and hope for the future’.9 It encompasses components of decisional control, cognitive 92 
control, behavioural control, emotional regulation and hope. Furthermore, the GCOS-93 
24 has demonstrated utility in service evaluation10 and quality improvement11 in 94 
genetic counseling services.  95 
It has been used in a study of 42 patients from a cardiology setting in USA by Ishon et 96 
al12, which demonstrated significant improvement in empowerment scores, which 97 
consequentially led to a greater awareness for surveillance recommendations in 98 
patients following genetic counseling. In the psychiatric context, a recent publication 99 
which used the GCOS-24 on a larger sample size showed an increase in 100 
empowerment following genetic counseling.13 Similar increases in empowerment were 101 
observed in Danish14, Dutch15 and Spanish11 validations of the GCOS-24.  102 
However, one limitation of the GCOS-24 is that psychometric evaluation of GCOS-24 103 
has largely involved classical test theory to date. Rasch analysis, a form of item 104 
response theory, provides significant insight into the psychometric properties of a 105 
scale,16,17 including: appropriate use of response categories; measurement precision; 106 
how well items ‘fit’ the underlying trait; how well the items measure a specific construct 107 
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(unidimensionality); targeting of item difficulty to participants’ ability; and differential 108 
item functioning (DIF; item bias). Rasch analysis has used by Grant et al18 to develop 109 
a short-form of the GCOS-24, to create a less burdensome scale for respondents that 110 
is similarly capable of capturing genetic counseling and testing-derived empowerment.  111 
 112 
The aims of this study were threefold. Firstly, we aimed to measure the improvement 113 
in patient empowerment, if any, following cancer genetic counseling using the GCOS-114 
24; with the secondary intention to identify and understand the factors associated with 115 
change in empowerment. Finally, we aimed to evaluate the psychometric properties 116 
of the GCOS-24 using Rasch analysis. 117 
 118 
MATERIALS AND METHODS 119 
 120 
Study Design 121 
This was a single arm, pre-post counseling (intervention) study conducted between 122 
May 2016 and May 2017 at the Cancer Genetics Service (CGS) at the National Cancer 123 
Centre Singapore (NCCS). We represent a specialized cancer genetics service with 124 
master’s level trained genetic counsellors working under a model of care adapted from 125 
the United States.19 The CGS sees predominantly Singaporean Chinese, Malay, and 126 
Indian patients with a personal and/or family history of cancer referred from general, 127 
surgical, oncologic and gynecological specialties. The GCOS-24 was offered to 128 
English-speaking, adult (≥21 years old) participants attending the CGS for the first 129 
time. Individuals with significant hearing impairment (questionnaire administration 130 
could take place over the telephone), cognitive impairment or any physical disability 131 
that prevented them from participating in the study were excluded. Written informed 132 
consent was obtained from all participants prior to the study and the study protocol 133 
was approved by the SingHealth Centralised Institutional Review Board (CIRB number 134 
2016/2367). 135 
 136 
Study procedure 137 
Participants were recruited face-to-face at the clinic, and after informed consent was 138 
obtained, they were asked to complete the pre-counseling GCOS-24 prior to their first 139 
genetic counseling session. The recruitment process was conducted by a research 140 
coordinator (HS). The pre-test genetic counseling session was led by a genetic 141 
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counsellor (STL, EC, or YC) or a clinical cancer geneticist (JN). It typically included a 142 
verbal discussion, with the use of visual aids, to provide information on the suspected 143 
genetic condition and cancer risk assessment based on personal and family history. 144 
Counselling skills are applied to facilitate coping and adaptation to the knowledge of a 145 
possible hereditary condition that runs in the family. The goal of the session is to reach 146 
a shared decision for genetic testing between the participant and their families, that is 147 
aligned with clinical recommendations. These sessions generally lasted between 30 148 
to 45 minutes. Participants had the option of completing the post-counseling GCOS-149 
24 via telephone, mail (written) or online methods (via Google survey), which was 150 
facilitated by a research coordinator (HS).  151 
 152 
During the counselling session, patients who met clinical testing criteria20 were offered 153 
genetic testing  to understand if they carried a pathogenic variant that predisposes 154 
them to cancer. There were also asymptomatic patients who came for genetic 155 
counseling as they were considering predictive testing for a familial condition. For 156 
patients who declined genetic testing, the post-counseling GCOS-24 was conducted 157 
2 weeks after their most recent counseling session. They were subsequently given an 158 
open date appointment. For patients who elected to undergo genetic testing, an in-159 
person result disclosure appointment (with STL, EC, YC or JN) was scheduled 2 to 6 160 
weeks after, dependent on turnaround time for testing ordered. These appointments 161 
typically last for 15 to 45 minutes, dependent on the type of result that was returned. 162 
The post-counseling GCOS-24 was administered 2 weeks after results disclosure (i.e. 163 
4 to 8 weeks after they completed the pre-counseling GCOS-24). 164 
 165 
Participants also completed a sociodemographic questionnaire which captured 166 
information about their gender, age, ethnicity, education status, genetic testing subsidy 167 
eligibility (eligible <SGD$1,800 monthly household income per person) and personal 168 
and family history of cancer. All data collected were anonymized. 169 
 170 
Cultural Adaptation of GCOS-24 171 
The GCOS-24 scale comprises 24 items across five domains (decisional control: three 172 
items, cognitive control: six items, behavioral control: eight items, emotional regulation: 173 
three items and hope: four items) which are rated on a seven-point Likert-type 174 
response scale ranging from ‘strongly agree’ to ‘strongly disagree’.21 Scores are 175 
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summed to provide an overall ‘empowerment’ and domain scores, where higher 176 
scores equal higher levels of empowerment. 177 
 178 
Because the GCOS-24 was developed in the UK, we first conducted some cognitive 179 
interviews with patients to assess the clarity and cross-cultural applicability of the 180 
GCOS-24 items for eliciting the required information.22 English-speaking patients aged 181 
21 and above, who had previously received genetic counseling at the CGS (n=12), 182 
were interviewed by trained interviewers. Interviews were audio-recorded and noted 183 
on standardized interview forms (Supplementary Materials 2). Responses were 184 
reviewed iteratively by the study team (JY, EF, MM & JN), and were used to guide 185 
edits to the GCOS-24 to improve clarity and comprehensibility of the items 186 
(Supplementary Materials 1).  There were no edits that changed the original meaning 187 
of items made (Supplementary Materials 1). Item 6 was modified to ‘I can see that 188 
good things (e.g. early detection & personalized screening) have come from having 189 
this condition in my family.’, where the examples of ‘early detection & personalized 190 
screening’ were added for better comprehension of what ‘good things’ might refer to. 191 
Item 10 was edited to ‘I don’t know what could be gained from each of the options (e.g. 192 
genetic testing) available to me.’, where the example of ‘genetic testing’ was included 193 
to explain what ‘options’ might refer to.  194 
 195 
Other Modifications of the GCOS-24 196 
The response scale was modified to include a ‘not applicable’ option for items relating 197 
to children (items 3, 13, 19, 21, 24) to provide an appropriate response for those 198 
participants who did not have and were not considering children in the future. This was 199 
an outcome of participant feedback we received from the cognitive interview exercise. 200 
While the addition of a ‘not applicable’ option response may influence the 201 
psychometric properties of the instrument as it creates the potential for missing data. 202 
Unlike in classical test theory, where missing data is a problem, Rasch analysis does 203 
not require complete data in order to generate person measure estimates. Therefore, 204 
the addition of a ‘not applicable’ option instead has improved the psychometric 205 
properties of the GCOS-24 as participants are not forced to answer items irrelevant to 206 
them, and any ensuing missing data will not affect the score provided by Rasch 207 
analysis. 208 
 209 
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Psychometric Assessment of the GCOS-24 210 
Rasch analysis was used to assess the psychometric properties of the adapted 211 
GCOS-24 using the Andrich rating scale model23 with Winsteps software (version 212 
3.92.1), Chicago, Illinois, USA.24 Rasch analysis transformed the ordinal ratings of the 213 
questionnaire into estimates of interval measures (expressed in log of the odds units, 214 
or logits) to allow for parametric testing.25 Item bias, thereby DIF was assessed for 215 
gender, age, educational status and presence of strong cancer family history to 216 
establish possible associations between baseline patient characteristics with 217 
magnitude of change in empowerment. To ensure that differences between the pre-218 
post counseling GCOS-24 scores were valid indicators of changes over time, pre-219 
counseling and post-counseling GCOS-24 data were stacked and DIF for time points 220 
was assessed. Absence of DIF was considered evidence of invariance over time.  221 
 222 
The adapted GCOS-24 displayed good precision (person separation index (PSI) > 2.0) 223 
and targeting (difference between person and item means <1.0) and no DIF for age, 224 
gender or time (Table 1). However, there was evidence of multidimensionality within 225 
the scale, with the eigenvalue for the first contrast >2.0, the variance explained by the 226 
first factor <50% and 3 mis-fitting items. Moreover, inspection of the standardized 227 
residual loadings for items indicated that 6 items were all relating to cognitive, 228 
behavioral or decisional control, loaded together. Therefore, based on this and the 229 
domain structure posited in the paper by Tirado et al,11 this supported the splitting of 230 
GCOS-24 into two discrete scales which were analyzed separately: 1) ‘Cognitive 231 
control’ [CC] (items 1-3, 5, 7, 10, 12-18, 23 and 24), which encompassed making 232 
informed decisions about the future, forward planning, decision-making, the utilization 233 
of socioeconomic and health-related resources and systems and the integration and 234 
contextualization into one’s own healthcare blueprint; and 2) ‘Emotional control’ [EC] 235 
(items 4, 6, 8, 9, 11, 19-22), which encompassed hope and emotional regulation. 236 
 237 
The CC scale initially displayed disordered thresholds (meaning that some of the 238 
response categories were not being used as intended) and multidimensionality with a 239 
high eigenvalue, low variance explained for the first contrast and two mis-fitting items 240 
(Table 1). However, upon iterative removal of items 13, 12, 18 and 5, measurement 241 
precision increased and the disordered thresholds and multidimensionality were 242 
largely resolved. The emotional domain had suboptimal precision (PSI <2.0) and 243 
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possible evidence of multidimensionality (eigenvalue of first contrast >2.0) (Table 1). 244 
However, only three items (4, 11 and 21) loaded together, which was not enough to 245 
form a separate scale; therefore, no further splitting was applied.  246 
 247 
Statistical Analysis 248 
Responses of participants who failed to complete the post-counseling GCOS-24 were 249 
excluded from analysis. The patient sample was characterized using mean (standard 250 
deviation [SD]) and median (interquartile range [IQR]) for description of normally and 251 
non-normally distributed data respectively. 252 
 253 
Wilcoxon signed-rank test was used to determine significant differences in the CC and 254 
EC domains post-intervention. We also present an item-by-item analysis as well as for 255 
the overall score. Additionally, effect sizes (ES; calculated as the difference in the 256 
mean scores between the baseline and follow-up examinations divided by the 257 
standard deviation (SD) of the scores for the baseline group) were utilized to determine 258 
clinically significant pre-post changes.26 An ES of 0.20-0.49 was considered small, 259 
0.50-0.79 as moderate and ≥0.80 as large.27 260 
 261 
The association of baseline characteristics with pre-post counseling changes in 262 
cognitive and emotional control domains were assessed by multiple regression models 263 
fit using the baseline characteristics as independent variables, with changes in CC 264 
and EC scores between baseline and post-counselling scores as dependent variables, 265 
respectively. For each model, variable selection was conducted via best subsets 266 
selection using the Akaike Information Criterion (AIC), leading to a final reduced 267 
model. All analyses were performed using Stata 15.0 (Statacorp LP, College Station, 268 
TX, USA), and statistical significance was defined as p < 0.05. 269 
  270 
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RESULTS 271 
Baseline Characteristics  272 
Of the 208 participants who were invited to participate in this study, 155 completed the 273 
GCOS-24 at both time-points and were included in the analysis (response rate: 274 
74.5%). Most were female (n=136, 87.7%), median age was 46 (18-71) years old, and 275 
majority were Chinese (n=111, 71.6%) (Table 2). Most patients (n=84, 54.2%) had a 276 
personal history of breast and/or ovarian cancer. Most patients had a personal (n=115, 277 
74.2%) and/or family history of cancer (n=109; 70.3%). The majority (n=110, 71.0%) 278 
of participants opted to proceed with genetic testing after counseling, where most 279 
consented to a multi-gene diagnostic test (n=96; 61.9%), while the remainder 280 
consented to a predictive test for a known familial pathogenic variant (n=14; 9.0%). 281 
Majority of our participants (n=79; 50.0%) received a negative or a variant of uncertain 282 
significance (VUS) genetic test result, others (n=21; 20.0%) received a positive genetic 283 
test result, while a minority (n=45; 29.0%) of participants declined genetic testing.  284 
 285 
 286 
GCOS-24 Scores Pre- and Post-Intervention  287 
 288 
Scores in both domains (CC and EC) (Supplementary Materials 3) increased 289 
following genetic counseling (Table 3). Overall post-intervention CC score [median 290 
1.23, IQR (-0.33 - 6.16)] was significantly higher (p<0.001) than the pre-intervention 291 
score [median 0.46, IQR (-1.10 - 3.55)]. A similar significant trend was noted for overall 292 
post-intervention EC scores [median 0.99, IQR (-1.14 - 6.41)] versus pre-intervention 293 
scores [median 0.61, IQR (-1.14 - 3.90)].  294 
 295 
In our item by item analysis for CC, several items showed substantial increases post-296 
intervention. For example, item 1 “I am clear … why I am attending the clinical genetics 297 
service” [pre-intervention: median 0.56, IQR (-2.33 - 3.55); post-intervention: median 298 
2.74, IQR (-1.01 - 6.16); p<0.001], item 7 “I can control how this condition affects my 299 
family”, item 10 “I don’t know what could be gained of the options (e.g. genetic testing) 300 
available to me”, [pre-intervention: median 0.36, IQR (-2.74 - 4.11); post-intervention: 301 
median 1.93, IQR (-2.74 - 6.16); p<0.001], and item 17 “I don’t know what I can do to 302 
change how to condition affects me / my children”, [pre-intervention: median 0.55, IQR 303 
(-2.55 - 4.30); post-intervention: median 2.12, IQR (-0.77 - 6.16); p<0.001] (Table 3) 304 
demonstrated the largest effect sizes.  305 
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 306 
The overall increase in scores for the EC domain was largely attributed to feeling more 307 
capable of coping with the condition post-counseling (item 9) [pre-intervention: median 308 
0.98, IQR (-2.04 - 3.90); post-intervention: median 0.98, IQR (-2.04 - 6.41), p=0.046], 309 
being more positive about the future (item 20) [pre-intervention: median 0.90, IQR (-310 
2.12 - 3.90); post-intervention: median 0.90, IQR (-2.12 – 6.41); p=0.024], and learning 311 
the positive aspects of having such a diagnosis (item 6) [pre-intervention: median 0.69, 312 
IQR (-2.33 – 3.90); post-intervention: median 0.69, IQR (-2.33 – 6.41); p=0.014]. 313 
However, it was notable that genetic counseling had little to no impact on participants’ 314 
feelings of being upset (item 4) and hopefulness for their children to have a rewarding 315 
family life (item 9).  316 
 317 
Baseline factors associated with change in CC and EC scores 318 
Compared to those without a family history of cancer, participants with a family history 319 
of cancer was were significantly associated with a smaller increment in CC scores (: 320 
0, -0.56; CI: -0.99, -0.03; p value = 0.036) (Table 4). Females was significantly 321 
associated with a greater increment in EC scores than males (: 0, -0.61; CI: -1-17, -322 
0.05; p value =0.033) (Table 5). Compared to participants who did not proceed with 323 
genetic testing, those who received a negative or VUS result were significantly 324 
associated with a greater increment in CC scores (: 0, 0.76; CI: 0.28, 1.24; p value 325 
=0.002) (Table 4) and EC scores (: 0, 0.78; CI: 0.35, 1.21; p value <0.001) (Table 326 
5). Similarly, participants who received a positive result were associated with greater 327 
increments in CC scores (: 0, 0.81; CI: 0.21, 1.42; p value =0.009) (Table 4) and EC 328 
scores (: 0, 0.64; CI: 0.10, 1.19; p value = 0.02) (Table 5) than participants who did 329 
not proceed with genetic testing. Of those who underwent genetic testing, the extent 330 
to which CC scores (Table 4) and EC scores (Table 5) increased were largely similar 331 
between participants who received positive results and those who received negative 332 
or VUS results.  333 
  334 
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DISCUSSION 335 
Our study explored the impact of cancer genetic counseling provided by the NCCS 336 
CGS on patient empowerment using the culturally-adapted GCOS-24 instrument. We 337 
found a statistically significant increase in EC and CC scores following genetic 338 
counseling and testing (in patients who underwent genetic testing). These findings 339 
provide empirical evidence that genetic counseling provided by the CGS improves 340 
patient empowerment, thus highlighting its value in the delivery of genetics services in 341 
Singapore. Secondly, our psychometric analysis of the adapted GCOS-24 found that 342 
while the instrument as a whole was multidimensional, two key domains, namely CC 343 
and EC, were valid measures to assess the extent of patient empowerment arising 344 
from genetic counseling and testing.  345 
 346 
Our study found that CC and EC were significantly improved post-genetic counseling 347 
and testing, and with the magnitude of improvement greater for the CC domain. These 348 
findings are concordant with recent systematic reviews of clinical genetics outcome 349 
research which have concluded that patients benefit from genetic counseling and 350 
testing, particularly in the areas of knowledge, ‘perceived personal control’ (PPC), 351 
improved risk perception accuracy, and reduced anxiety.28,29  Our findings were largely 352 
concordant with that of Tirado et al,11 who found that the overall GCOS-24 score 353 
improved post-counseling and testing, specifically the cognitive domain. This is 354 
consistent with our findings that patients were in a better position to establish control 355 
over their conditions, namely by managing how it affects their families. We also found 356 
that patients felt better equipped to navigate educational, financial and social 357 
resources available to consequentially make better autonomous decisions that are 358 
potentially life-altering for them and their descendants. Genetic counseling and testing 359 
was also observed to improve patients’ knowledge of what they could do to change 360 
the impact of the condition.  361 
With a growing demand for cancer genetic services in Singapore6 and as the inclusion 362 
of genetic counsellors in patient care is increasingly found to be cost-effective,30 our 363 
study demonstrates that this model of care is beneficial for patients in the Asian 364 
context, where patients benefit from increased empowerment following genetic 365 
counseling and testing. Genetic counseling has been found to provide patients with a 366 
better knowledge of surveillance and risk-reducing options,31 which was subsequently 367 
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reported to empower patients in their decision-making regarding genetic testing by 368 
Augestad et al.32 369 
Notably, there were items pertaining to feelings of sadness and hopelessness in the 370 
EC domain in which no statistically significant improvement was reflected. This is 371 
similar to Tirado et al11 who highlighted a lack of significant improvement in the 372 
emotional regulation domain of the GCOS-24 (items 4, 11, and 21), which overlaps 373 
with the EC category defined here. These findings suggest a place for hope-based 374 
inventions, warranting research to understand how hope can be appropriately 375 
introduced during genetic counseling. Hope-based interventions, in the form of group 376 
therapy sessions where psychological questionnaires were administered, were found 377 
to be effective in allaying anxiety of patients with a predisposition to psychological 378 
conditions who were undergoing genetic testing.33 Hope-based interventions, focuses 379 
on prioritizing hope in patients and encourages goal-directed thinking,34 which enable 380 
recipients to achieve a higher dispositional hope. When achieved, patients benefit from 381 
greater psychological well-being, improved health knowledge, adoption of preventive 382 
health behaviors and adaptation to chronic illnesses. In the same vein, the reciprocal 383 
engagement model (REM) for genetic counseling provides a useful framework for the 384 
design of counseling strategies for the delivery of genetic results. These strategies 385 
have been proven to personalize the result communication and risk counseling 386 
process,35 which could be a way to improve emotional control in patients receiving 387 
genetic results. The incorporation of such interventions in genetic counseling practice 388 
may promote the delivery of holistic care, whilst presenting a systematic approach to 389 
instilling and improving emotional regulation in patients. Our findings highlight the 390 
growing importance of addressing emotional issues in genetic counseling. This is 391 
consistent with a review of genetic risk communication measures, which found 392 
emotional counseling elements to confer more benefit than informational elements.36 393 
In our study, higher empowerment levels were observed in patients who elected to 394 
proceed with genetic testing over patients who declined testing, suggesting that 395 
patients who underwent testing possessed a better understanding of their condition, 396 
as well as medical and non-medical resources available. Furthermore, they were also 397 
the group identified with higher emotional control levels, which meant they could cope 398 
better with new information that genetic testing provides them with. A better 399 
Page 14 of 21 
 
understanding of the motivations and deterrents for genetic testing in at-risk patients 400 
is also warranted. 401 
 402 
Rasch analysis was used to optimize the psychometric properties of the GCOS-24, 403 
which found that the scale was multidimensional in its overall form. Multidimensionality 404 
is problematic as patients respond differently to subsets of items and, if an overall 405 
score is used, true changes in sub-domains may be masked or neutralized, thus 406 
affecting the study conclusions. Therefore, we recommend that an overall score be 407 
avoided for the GCOS-24 and that separate CC and EC domain scores should be 408 
reported instead. Our findings demonstrate the importance of using Rasch analysis to 409 
verify and optimize the psychometric properties of PROMs in clinical research and our 410 
application of Rasch analysis to the GCOS-24 represents a useful contribution to 411 
clinicians and researchers hoping to measure patient-reported outcomes such as 412 
patient empowerment following genetic counseling. However, given our relatively 413 
small sample size in a culturally-diverse Asian population, further studies of similar 414 
design are required to confirm our findings. Recently, another PROM has been 415 
developed for the measurement of outcomes research related to risk communication 416 
in genetic counseling as part of the FOCUS-GC (Framework for Outcomes of Clinical 417 
Communication Services in Genetic Counseling).37 Further psychometric evaluation 418 
would be useful to determine if it is a useful PROM for measuring clinically significant 419 
changes in empowerment.  420 
 421 
 Strengths of our study include a cross-cultural adaptation of the GCOS-24 in an Asian 422 
population and our use of Rasch analysis to optimize the psychometric properties of 423 
the scale and enhance measurement precision and improve the robustness of our 424 
results; a well-characterized cohort with an equal distribution in age and a variety of 425 
cancers with suspicions for hereditary conditions, such as breast, ovarian, and 426 
colorectal cancers; inclusion of unaffected patients allowed us to measure genetic 427 
counseling-derived empowerment in individuals with a family history suggestive of a 428 
genetic condition.  429 
 430 
There are several limitations to this study. Firstly, patient empowerment as 431 
operationalized in the GCOS-24 may not capture certain important patient reported 432 
outcomes that result from genetic counseling. This is complicated by the lack of 433 
consensus on tools reliable for such an assessment and what constitutes genetic 434 
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counseling-derived benefits.4 The study conducted in U.K. utilized the EQ-5D scale 435 
and an internal audit survey tool for comparison, while our study was limited to the 436 
GCOS-24. Without EQ-5D, the calculation of Quality Adjusted Life Years (QALY) 437 
delivered to patients seen by the CGS was unattainable, which demonstrates the 438 
limitation of the GCOS-24 for use in economic evaluation of a service. However, in a 439 
study comparing EQ-5D against the GCOS-24,11 EQ-5D was found to have 440 
problematic ceiling effects, with no detectable pre-post changes in scores, as it fails to 441 
capture patient outcomes of clinical genetics. Second, the post- GCOS-24 was 442 
administered relatively quickly after their genetic counseling session, which denied a 443 
longitudinal follow up of the patient’s emotional status (including that of hope), which 444 
might prove more effective in capturing patients with a reduced ability for emotional 445 
regulation. It would be meaningful to clarify if poor emotional control is attributed to 446 
pre-existing conditions or in fact exacerbated by genetic counseling. Studies have 447 
identified several risk factors that predispose patients to long-term post-testing 448 
distress, namely a pre-existing history of anxiety, depression, or psychiatric 449 
conditions,38-44 as well as pre-existing heightened cancer worry, elevated cancer risk 450 
perception, poor support networks, and an unfavorable test result. Voorwinden, 451 
Jaspers 45 Screening for patients who demonstrate these prognostic variables for 452 
increased psychological distress from genetic testing, would allow for the 453 
personalization of a counseling program for them, thereby facilitating better 454 
psychological adaptation to their condition.  455 
Third, neither the CC or EC domains achieved perfect fit to the Rasch model, both 456 
demonstrating some evidence of multidimensionality, while the EC domain 457 
demonstrated suboptimal precision. Therefore, the results should be interpreted with 458 
caution and future studies with larger sample sizes are required to confirm our domain 459 
structure.  460 
 461 
CONCLUSION 462 
In conclusion, our study revealed that patients who received cancer genetic counseling 463 
by trained genetics clinicians experienced a significant improvement in empowerment.  464 
However, more emphasis must be placed on cultivating hope and alleviating emotions 465 
of distress in patients during genetic counseling. Finally, our study demonstrated the 466 
utility of Rasch analysis in revealing multidimensionality of the GCOS-24, for which 467 
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scores for cognitive control and emotional regulation should be reported separately.  468 
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